EGFR and prostate carcinoma: The combined effects of luteolin and gefinitib, a selective tyrosine kinase inhibitor that suppresses both EGFR and the kinase activity of cyclin G-associated kinase (GAK), on PC-3 prostate cancer cells were investigated in 2014 [177].